The combination of PF3758309 (PF-309) plus oxaliplatin (OXA) enhances the inhibition of tumor growth in vivo. (IMAGE)
Caption
(A) The scheme of medication on tumor-bearing mice.
(B) Images of tumor-bearing mice from each treatment group at the end of the experiment.
(C) Images of the tumors dissected from the animals.
(D) Body weight of mice during the treatment period.
(E) Tumor weight of each group.
(F) Tumor volume measurements over time in different groups.
(G) Western blotting analysis of mTOR, CD44, and SAA1 protein levels in tumor tissues from different treatment groups.
(H–J) Quantitative real-time PCR analysis of MTOR (H), CD44 (I), and SAA1 (J) mRNA expression levels in tumor tissues from different treatment groups. The data were presented as mean ± standard deviation, with statistical significance indicated (ns, no significance; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001).
Credit
Rongtian Pan, Renrui Zou, Ying Sui, Fei Wu, Dongfeng Wang, Yuan Zhang, Shaorong Yu
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND